OAM
ACOR

Oppenheimer Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Oppenheimer Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-37
Closed -$13K – 1639
2019
Q3 		$13K Buy
37
+1
+3% +$544 ﹤0.01% 1491
2019
Q2 		$33K Buy
36
+2
+6% +$2.46K ﹤0.01% 1425
2019
Q1 		$55K Buy
34
+11
+48% +$19.8K ﹤0.01% 1343
2018
Q4 		$44K Buy
+23
New +$50K ﹤0.01% 1374

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Oppenheimer Asset Management's ACOR Position: Q4 2019 in Review

Oppenheimer Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 37 shares — an estimated $13K sold.

Oppenheimer Asset Management first reported a position in ACOR in Q4 2018 and held it in 4 quarters. The position peaked at $55K in Q1 2019. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

  • Oppenheimer Asset Management reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Oppenheimer Asset Management sold 37 Acorda Therapeutics shares in Q4 2019, an estimated $13K.
  • Oppenheimer Asset Management first reported a position in Acorda Therapeutics in Q4 2018 and held it in 4 quarters.
  • Oppenheimer Asset Management's Acorda Therapeutics position peaked at $55K in Q1 2019.
  • 121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Oppenheimer Asset Management's 13F filing for Q4 2019, filed 7 Feb 2020.